

124B.2 Reporting required.

1. Effective July 1, 1990, a report to the board shall be submitted in accordance with [this chapter](#) by a manufacturer, retailer, or other person who sells, transfers, or otherwise furnishes to any person in this state any of the following substances:

- a. Anthranilic acid, its esters, and its salts.
- b. Benzyl cyanide.
- c. Ethylamine and its salts.
- d. Ergonovine and its salts.
- e. Ergotamine and its salts.
- f. 3,4 - methylenedioxyphenyl-2-propanone.
- g. N-acetylanthranilic acid, its esters, and its salts.
- h. Norpseudoephedrine, its salts, optical isomers, and salts of optical isomers.
- i. Phenylacetic acid, its esters, and its salts.
- j. Piperidine and its salts.
- k. Methylamine and its salts.
- l. Propionic anhydride.
- m. Isosafrole.
- n. Safrole.
- o. Piperonal.
- p. N-methylephedrine, its salts, optical isomers, and salts of optical isomers.
- q. N-methylpseudoephedrine, its salts, optical isomers, and salts of optical isomers.
- r. Hydriodic acid.
- s. Benzaldehyde.
- t. Nitroethane.
- u. Gamma-Butyrolactone (also known as GBL; Dihydro-2(3H)-furanone; 1,2-Butanolide; 1,4-Butanolide; 4-Hydroxybutanoic acid lactone; or gamma-hydroxy-butyric acid lactone).
- v. Red phosphorus.
- w. White phosphorus (another name: yellow phosphorus).
- x. Hypophosphorous acid and its salts (including ammonium hypophosphite, calcium hypophosphite, iron hypophosphite, potassium hypophosphite, manganese hypophosphite, magnesium hypophosphite, and sodium hypophosphite).
- y. Iodine.
- z. N-phenethyl-4-piperidone (NPP).
- aa. Ergocristine and its salts.

2. The board shall administer the regulatory provisions of [this chapter](#) and may, by rule adopted pursuant to [chapter 17A](#), add a substance to or remove a substance from the list in [subsection 1](#). In determining whether to add or remove a substance from the list, the board shall consider the following:

- a. The likelihood that the substance may be used as a precursor in the illegal production of a controlled substance.
- b. The availability of the substance.
- c. The appropriateness of including the substance under [this chapter](#) or under [chapter 124](#).
- d. The extent and nature of legitimate uses for the substance.

3. On or before November 1 of each year, the board shall inform the general assembly of any substances added, deleted, or changed in the list contained in [this section](#) and shall provide an explanation of any addition, deletion, or change.

[90 Acts, ch 1251, §11](#)

[C91, §204B.2](#)

[C93, §124B.2](#)

[2000 Acts, ch 1140, §17, 18; 2002 Acts, ch 1108, §2, 3; 2003 Acts, ch 53, §10; 2008 Acts, ch 1010, §5; 2009 Acts, ch 36, §1; 2012 Acts, ch 1122, §6](#)

Referred to in [§124B.1](#), [§124B.3](#), [§124B.6](#)